PlexusDx helps you navigate this critical decision with personalized medical guidance
Obesity Landscape - Final Thoughts Dosing The GLP-1 RA obesity market, driven by injectables, has seen historic levels of success, and near-term entrants are likely to provide more dosing options within the GLP-1 or GLP-1/GIP class Weight Loss Novel drugs in development are likely to be approved within the next 5 years, with improved weight loss efficacy compared to what Wegovy and Zepbound have demonstrated Body Comp The coming years will likely see increased data on muscle preservation and the quality of weight loss with novel MoAs, even if used in combination with GLP-1/incretin-targeting agents As the obesity market matures, how will patients think about the tradeoffs between efficacy, safety, and dosing/convenience with the availability of new drugs and more data
Multifunctional nanoparticles for genetic engineering and bioimaging of natural killer (NK) cell therapeutics
ROSE-010 (300 g) is more effective than a placebo for all irritable bowel syndrome subtypes, with consistent effects across trials
The streamlined approach is expected to set a new precedent for future litigation involving large numbers of plaintiffs
Integrating Semaglutide Injections into a Broader Weight Management Plan Combining Injections with Nutrition and Lifestyle Changes Semaglutide injection for weight loss is most effective when used alongside thoughtful nutrition and consistent lifestyle modifications